• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 ULTRA RESILIA TRANSCATHETER HEART VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 ULTRA RESILIA TRANSCATHETER HEART VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED Back to Search Results
Model Number 9755RSL29A
Device Problem Material Deformation (2976)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 12/26/2023
Event Type  malfunction  
Manufacturer Narrative
The investigation is ongoing.H3 other text : the device was not returned.
 
Event Description
As reported by a field clinical specialist (fcs), during the procedure of a 29 mm sapien 3 ultra resilia valve in the aortic position via transfemoral approach.The initial valve got stuck within the 16fr esheath and could not be advanced through, because tine of stent was sticking out of the side of the sheath.Per the fcs, the event is likely more of patient anatomy related.The patients femoral anatomy was tight/diseased (per physician 5.5-6mm).The valve was also prepped by hospital staff with my oversight.The person crimping the valve has not crimped a valve in a long time and though it appeared the device was prepped correctly, this could be a possible cause.The second prepped 29mm valve serial was delivered and implanted without an issue, though it was very hard to push valve through the sheath.There is no clinical issue to the patient and patient is doing well in post op.2023-29390-01 - 2nd esheath.2023-29390-02 - 1st esheath.2023-29390-03 - 1st valve.
 
Manufacturer Narrative
A supplemental mdr is being submitted for correction and additional information.The following sections of this report have been updated: corrected h.6 component codes and investigation conclusions and investigation findings.Added new information to h.6 type of investigation.The device was not returned to edwards lifesciences for evaluation.Without the device returned for evaluation, visual inspection, functional testing and dimensional analysis were unable to be completed.Imagery was provided from the site and revealed the following: one (1) valve strut appeared punctured through sheath.A review of the risk management documentation was performed, and no evidence of product non-conformances or labeling/ifu inadequacies were identified in the evaluation.The complaint was confirmed based on evaluation of provided device imagery.Available information suggests that patient factors (undersized vessel) and procedural factors (excessive manipulation) likely contributed to the event as the following was reported: ''the event is likely more of patient anatomy related.The patient's femoral anatomy was tight/diseased (per physician 5.5-6mm)''.Per the training manual, the minimum vessel diameter required for 29mm thv and 16f esheath+ is 6.0mm.Undersized vessels (e.G.Due to anatomical variation, pre-existing stent or graft, scar tissue, or fibrosis) can create a restricted pathway or constrained condition resulting in difficulty during sheath expansion and increased resistance during the advancement of the delivery system.Excessive device manipulation or high push force can lead to the valve struts interacting with the sheath shaft and result in the strut damage at the valve inflow side.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.No ifu/labeling/training manual inadequacies were identified.Therefore, no corrective or preventative action nor product risk assessment is required at this time.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS SAPIEN 3 ULTRA RESILIA TRANSCATHETER HEART VALVE
Type of Device
AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
renee van dorne
1 edwards way
irvine, CA 92614
9492506385
MDR Report Key18518344
MDR Text Key333378314
Report Number2015691-2024-00426
Device Sequence Number1
Product Code NPT
UDI-Device Identifier00690103215823
UDI-Public(01)00690103215823(17)260417(11)2304182110596857
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P140031
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,User Facility,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 03/01/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model Number9755RSL29A
Device Lot Number10596857
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 12/26/2023
Initial Date FDA Received01/16/2024
Supplement Dates Manufacturer Received02/29/2024
Supplement Dates FDA Received03/01/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured05/12/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient SexMale
-
-